Alector: “We are developing drug leads against unique, genetically-validated neuro-immune targets through a novel, hypothesis-driven approach to neurodegeneration. We thankFierceBiotech for recognizing the potential of our strategy,” said Arnon Rosenthal, co-founder, president and CEO of Alector. Release
Arvinas: “We are thrilled to be selected by FierceBiotech to be among the top private biotech firms globally,” Manuel Litchman, president and chief executive officer of Arvinas, said. “This award recognizes the dedication of our employees, our founder, Dr. Craig Crews, and our partners to bring our PROTAC technologies to patients with … Read more